$ 1.55
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors...
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks.
Target Price
The average target price of LUNG is 7.2 and suggests 366% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
